RPG Life Sciences Ltd

RPG LifeScience. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

RPG Life Sciences Ltd

₹ 1,985 0.04%
02 Feb 4:01 p.m.
rpglifesciences.com BSE: 532983 NSE: RPGLIFE
About

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]

Key Points

Business Overview:[1]
RPGLS is a part of the RPG Group. It started as a joint venture with G.D Searle and was renamed when G.D Searle withdrew its India operations. Currently, the group has major listed companies like KEC International, CEAT, Zensar Tech, etc.
RPGLS is an integrated research based pharmaceutical company operating in domestic and international markets in branded formulations, global generics and APIs

Website BSE NSE
  • Market Cap ₹ 3,278 Cr.
  • Current Price ₹ 1,985
  • High / Low ₹ 2,725 / 1,772
  • Stock P/E 31.2
  • Book Value ₹ 335
  • Dividend Yield 1.01 %
  • ROCE 32.8 %
  • ROE 25.5 %
  • Face Value ₹ 8.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 28.5% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
  • Company has been maintaining a healthy dividend payout of 27.1%

Cons

  • The company has delivered a poor sales growth of 11.7% over past five years.
  • Earnings include an other income of Rs.131 Cr.
  • Debtor days have increased from 35.3 to 48.5 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
131 118 148 154 154 127 165 172 173 143 169 182 180
101 103 116 116 116 106 126 126 124 118 133 143 140
Operating Profit 29 16 32 37 38 21 39 46 49 25 35 39 40
OPM % 22% 13% 22% 24% 25% 16% 24% 27% 28% 18% 21% 21% 22%
1 2 2 2 2 2 2 -25 3 115 5 16 -5
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 4 4 4 4 4 4 5 5 5 5 5 5 5
Profit before tax 26 14 30 35 36 18 36 15 47 135 35 49 29
Tax % 26% 25% 26% 26% 26% 25% 26% 72% 26% 13% 26% 25% 24%
19 10 22 26 26 13 27 4 35 117 26 37 22
EPS in Rs 11.55 6.26 13.36 15.64 16.00 8.01 16.18 2.54 21.12 70.95 15.90 22.28 13.38
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
236 242 279 294 344 330 376 389 440 513 582 653 674
224 228 256 274 306 296 315 318 353 408 453 493 534
Operating Profit 12 14 23 20 38 34 60 71 87 104 129 161 140
OPM % 5% 6% 8% 7% 11% 10% 16% 18% 20% 20% 22% 25% 21%
66 1 1 18 1 1 -5 1 3 4 7 95 131
Interest 3 3 2 4 5 5 3 2 1 1 1 2 1
Depreciation 11 11 10 11 14 15 16 16 16 16 17 21 21
Profit before tax 65 1 12 23 20 15 36 54 73 92 118 233 249
Tax % 18% 0% 0% 10% 34% 28% 20% 25% 30% 26% 26% 21%
53 1 12 21 13 11 29 40 51 68 88 183 203
EPS in Rs 32.29 0.60 7.03 12.70 8.13 6.54 17.54 24.19 31.13 40.90 53.00 110.79 122.51
Dividend Payout % 6% 132% 23% 22% 30% 37% 23% 30% 31% 29% 30% 22%
Compounded Sales Growth
10 Years: 10%
5 Years: 12%
3 Years: 14%
TTM: 6%
Compounded Profit Growth
10 Years: 63%
5 Years: 29%
3 Years: 31%
TTM: 10%
Stock Price CAGR
10 Years: 23%
5 Years: 36%
3 Years: 35%
1 Year: -20%
Return on Equity
10 Years: 20%
5 Years: 24%
3 Years: 25%
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 113 112 120 134 142 147 163 203 243 294 362 517 541
15 33 23 45 54 36 12 2 1 0 0 0 0
56 39 49 55 82 54 78 85 88 112 138 127 152
Total Liabilities 196 197 205 247 291 251 267 303 345 419 513 658 706
106 105 109 137 131 128 123 113 104 124 114 172 179
CWIP 1 1 2 2 9 17 10 12 31 25 96 16 27
Investments 0 0 0 0 0 0 0 0 0 58 91 127 93
89 92 94 108 152 106 134 178 210 211 212 343 407
Total Assets 196 197 205 247 291 251 267 303 345 419 513 658 706

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-6 -2 33 7 15 46 50 58 65 91 94 78
59 -10 -15 -30 -16 -19 -11 -8 -35 -106 -79 -42
-54 12 -18 23 0 -26 -39 -10 -14 -17 -20 -27
Net Cash Flow 0 -0 -0 1 -1 0 0 40 17 -32 -5 9

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 56 61 48 49 72 43 62 54 27 27 31 48
Inventory Days 180 149 156 163 171 136 133 162 214 203 200 159
Days Payable 176 109 135 102 165 83 127 132 117 138 140 135
Cash Conversion Cycle 60 101 70 110 78 96 68 84 124 91 90 72
Working Capital Days 30 27 26 20 22 20 41 52 47 33 25 45
ROCE % 2% 2% 9% 10% 13% 10% 23% 27% 31% 33% 35% 33%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
72.82% 72.82% 72.82% 72.82% 72.82% 72.82% 72.82% 72.95% 72.95% 72.95% 72.95% 72.95%
0.38% 0.33% 0.46% 0.56% 0.90% 1.15% 1.35% 1.30% 1.46% 1.35% 1.11% 1.00%
0.11% 0.27% 1.57% 1.77% 2.16% 2.61% 5.45% 6.06% 6.14% 6.49% 6.70% 7.04%
26.70% 26.58% 25.15% 24.85% 24.12% 23.44% 20.40% 19.70% 19.46% 19.22% 19.23% 19.01%
No. of Shareholders 20,83720,22621,08821,86622,13722,23223,48124,89124,86725,83226,65725,905

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Jan 2026
    Transcript
    AI Summary
    PPT
  • Oct 2025
    Transcript PPT REC
  • Jul 2025
    Transcript
    AI Summary
    PPT
  • Jun 2025
    Transcript
    AI Summary
    PPT
  • Apr 2025
    Transcript PPT REC
  • Nov 2024
    Transcript
    AI Summary
    PPT
  • Sep 2024
    Transcript
    PPT
    REC
  • Jul 2024
    Transcript
    AI Summary
    PPT
  • Jun 2024
    Transcript
    AI Summary
    PPT
  • May 2024
    Transcript PPT
  • Feb 2024
    Transcript
    AI Summary
    PPT
  • Oct 2023
    Transcript PPT
  • Jul 2023
    Transcript
    AI Summary
    PPT
  • Jun 2023
    Transcript
    AI Summary
    PPT
  • May 2023
    Transcript PPT
  • Feb 2023
    Transcript
    AI Summary
    PPT
  • Feb 2023
    Transcript
    AI Summary
    PPT
  • Oct 2022
    Transcript PPT
  • Sep 2022
    Transcript
    AI Summary
    PPT
  • Aug 2022
    Transcript
    AI Summary
    PPT
  • May 2022
    Transcript PPT
  • Feb 2022
    Transcript
    AI Summary
    PPT
  • Jan 2022
    Transcript
    AI Summary
    PPT
  • Nov 2021
    Transcript PPT
  • Aug 2021
    Transcript
    AI Summary
    PPT
  • Jun 2021
    Transcript
    AI Summary
    PPT
  • Jun 2019
    Transcript
    AI Summary
    PPT
  • Jun 2018
    Transcript
    AI Summary
    PPT
  • Nov 2017
    Transcript
    AI Summary
    PPT
  • Jun 2017
    Transcript
    AI Summary
    PPT
  • Nov 2016
    Transcript
    AI Summary
    PPT
  • Jun 2016
    Transcript
    AI Summary
    PPT